HOME > TOP STORIES
TOP STORIES
-
BUSINESS Middle East Turmoil Raises Fears over API Shipments as Key Airports Shut
March 3, 2026
-
ORGANIZATION EFPIA Report Calls Japan a “Cautionary Tale” in 10-Country Biopharma Strategy Review
March 2, 2026
-
BUSINESS Ono, AstraZeneca to End Japan Co-Promotion of Forxiga
March 2, 2026
-
BUSINESS Asahi Kasei to Buy German Antiviral Specialist Aicuris for 143.1 Billion Yen
February 27, 2026
-
BUSINESS Japan Pharma Market Up 1.7% in 2025, 5th Straight Year of Growth: IQVIA
February 26, 2026
-
COMMENTARY G1 Rule to Hit Originator Biologics for First Time, Impact Seen for Up to 13 Brands
February 25, 2026
-
BUSINESS Nippon Kayaku Aims to Lift New Drug Sales Ratio to 30%, Bolsters Oncology Push
February 25, 2026
-
REGULATORY Japan Panel to Review Haihe’s PI3Kα Inhibitor, MSD’s HIV Med, and More on March 2
February 24, 2026
-
BUSINESS Daiichi Sankyo Taps Ex-Novartis CMO John Tsai as R&D Head
February 24, 2026
-
BUSINESS DMD Gene Therapy Elevidys Hits Japan Market at Record Price
February 20, 2026
-
REGULATORY Japan Approves AbbVie’s Aquipta, Novo’s IcoSema, Pfizer’s Tukysa, and More
February 20, 2026
-
REGULATORY Two iPSC-Derived Products Now in Line for Conditional Approval
February 20, 2026
-
BUSINESS Japan IP High Court Upholds Invalidation of Key Trazenta Dosage Patent
February 19, 2026
-
BUSINESS ONODERA GT Pharma Targets 2026 Filings for Two Gene Therapies
February 19, 2026
-
COMMENTARY Hisamitsu’s MBO: Is Shareholder Accountability Trust-Building or a Shackle?
February 18, 2026
-
BUSINESS Fycompa Generics Approved despite Extended Patent, Hydrate Switch in Play?
February 17, 2026
-
BUSINESS Espha Snags Bilanoa AG in Final Pre-Rule Approval Window
February 17, 2026
-
REGULATORY 10 Firms Win Approval for Bilanoa Generics, 2 Contenders for Fycompa
February 17, 2026
-
REGULATORY MHLW to Brand OTC-Like Drug Cost Rule as “Partially Non-Insured Care”
February 17, 2026
-
REGULATORY Japan Panel to Review Sumitomo, Cuorips iPSC Products on Feb. 19
February 16, 2026
ページ
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
